Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The brain is protected from nutrient excess.

F V deFeudis

    Life Sciences
    |January 5, 1987
    PubMed
    Summary
    This summary is machine-generated.

    Neurotransmitter precursor therapy often fails due to high brain barrier metabolism and intraneuronal degradation. These factors limit precursor effectiveness for neurologic and psychiatric disorders.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Interactions of verapamil, D 600, flunarizine and nifedipine with cerebral histamine-receptors.

    Neurochemistry international·2010
    Same author

    GABA and "neuro-cardiovascular" mechanisms.

    Neurochemistry international·2010
    Same author

    Central GABA-ergic systems and feeding behavior.

    Neurochemistry international·2010
    Same author

    Separate binding sites in rat brain synaptic membranes for l-cysteine sulfinate and for l-glutamate.

    Neurochemistry international·2010
    Same author

    Do different populations of GABA-receptors exist in the vertebrate CNS?

    Neurochemistry international·2010
    Same author

    Effects of psychoactive agents on GABA binding processes.

    Neurochemistry international·2010

    Area of Science:

    • Neuroscience
    • Pharmacology
    • Biochemistry

    Background:

    • Neurotransmitter precursor administration is a proposed therapeutic strategy for neurologic and psychiatric disorders.
    • Clinical efficacy has been limited, with inconsistent neurophysiological effects observed despite precursor administration.

    Purpose of the Study:

    • To investigate the reasons behind the limited efficacy of neurotransmitter precursor loading therapies.
    • To highlight the role of the blood-brain barrier's metabolic activity and subsequent degradation pathways.

    Main Methods:

    • Review of existing literature on precursor transport and metabolism.
    • Analysis of factors affecting precursor bioavailability in the brain.

    Main Results:

    Related Experiment Videos

    • Cerebrovascular endothelial cells possess high metabolic activity, degrading precursors before they reach brain parenchyma.
    • Studies measuring precursor transport across the blood-brain barrier may be confounded by endothelial metabolism.
    • Intraneuronal degradation mechanisms can further limit the neurophysiological impact of precursors that do reach the brain.

    Conclusions:

    • The ineffectiveness of precursor-loading therapies is likely due to extensive metabolism by endothelial cells and intraneuronal degradation.
    • Re-evaluation of transport indices in precursor studies is necessary, accounting for endothelial metabolic effects.
    • Alternative strategies may be required to overcome these metabolic barriers for effective precursor-based therapies.